Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 10.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | Erasca, Inc. |
|---|---|
| Ticker | ERAS |
| CIK | 0001761918 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,88 Mrd. USD |
| Beta | 1,05 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -124,546,000 | -0.44 | 396,154,000 | 325,171,000 | |
| 2025-09-30 | 10-Q | -30,612,000 | -0.11 | 420,401,000 | 347,886,000 | |
| 2025-06-30 | 10-Q | -33,876,000 | -0.12 | 445,386,000 | 372,258,000 | |
| 2025-03-31 | 10-Q | -30,966,000 | -0.11 | 471,244,000 | 399,502,000 | |
| 2024-12-31 | 10-K | -161,650,000 | -0.69 | 502,526,000 | 423,499,000 | |
| 2024-09-30 | 10-Q | -31,200,000 | -0.11 | 528,896,000 | 450,042,000 | |
| 2024-06-30 | 10-Q | -63,201,000 | -0.29 | 525,744,000 | 451,087,000 | |
| 2024-03-31 | 10-Q | -35,017,000 | -0.23 | 370,022,000 | 288,409,000 | |
| 2023-12-31 | 10-K | -125,042,000 | -0.83 | 395,297,000 | 316,686,000 | |
| 2023-09-30 | 10-Q | -30,361,000 | -0.20 | 419,406,000 | 338,975,000 | |
| 2023-06-30 | 10-Q | -31,781,000 | -0.21 | 440,662,000 | 362,705,000 | |
| 2023-03-31 | 10-Q | -33,199,000 | -0.22 | 467,542,000 | 386,452,000 | |
| 2022-12-31 | 10-K | -242,805,000 | -1.99 | 514,909,000 | 411,853,000 | |
| 2022-09-30 | 10-Q | -35,489,000 | -0.29 | 446,429,000 | 365,319,000 | |
| 2022-06-30 | 10-Q | -35,608,000 | -0.30 | 444,823,000 | 395,067,000 | |
| 2022-03-31 | 10-Q | -36,458,000 | -0.31 | 475,469,000 | 424,662,000 | |
| 2021-12-31 | 10-K | -122,764,000 | -1.85 | 501,415,000 | 456,528,000 | |
| 2021-09-30 | 10-Q | -46,069,000 | -0.46 | 521,948,000 | 482,991,000 | |
| 2021-06-30 | 10-Q | -28,214,000 | -1.20 | 210,383,000 | -149,997,000 | |
| 2021-03-31 | 10-Q | -18,017,000 | -129,259,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Garner Ebun | Officer, Chief Legal Officer | Open Market Sale | -80,000 | 16.40 | -1,312,000.00 | -172,4% | |
| 2026-03-04 | Morris Shannon | Officer, Chief Medical Officer | Open Market Sale | -20,000 | 15.04 | -300,760.00 | -39,5% | |
| 2026-01-07 | Garner Ebun | Officer, General Counsel & Corp. Sec. | Open Market Sale | -120,000 | 5.59 | -670,812.00 | -88,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.